Search

Your search keyword '"Aurrekoetxea, Igor"' showing total 19 results

Search Constraints

Start Over You searched for: Author "Aurrekoetxea, Igor" Remove constraint Author: "Aurrekoetxea, Igor" Journal journal of hepatology Remove constraint Journal: journal of hepatology
19 results on '"Aurrekoetxea, Igor"'

Search Results

1. FRI-472-YI Mitochondrial metabolism is disrupted by ciprofloxacin preventing cholangiocarcinoma cell proliferation

2. THU-210 Dysfunctional activation of the DNA damage response is associated with MASLD progression through an E2F2-dependent mechanism

3. FRI-343-YI APAP induced liver damage is prevented by activation of PPARgamma and PPAR-alpha

4. OS-101-YI Remodelling of hepatocyte cholesterol metabolism mediates colorectal liver metastasis

5. TOP-229-YI The E2F2 target glycerophosphodiester phosphodiesterase domain containing 3 is involved in MASLD progression to HCC and related dyslipidemias

6. The E2F2-miR34a-5p axis is involved in the biliary metabolism dysregulation in NASH

7. Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism

8. E2F2 deficiency protects from acetaminophen-induced hepatotoxicity while E2F1 is required to prevent the devastating effects

9. E2F2-promoted DNA damage in NASH worsens the metabolic scenario

10. S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease

11. The uptake of extracellular lipids promotes cholangiocarcinoma progression

12. miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC

13. Methionine adenosyltransferase 1a antisense oligonucleotides induce the fibroblast growth factor 21-driven recovery from obesity and associated hepatoesteatosis

14. The DNA damage response is involved in the metabolic dysregulation of MAFLD patients via inefficient fatty acid oxidation

15. WED-408 - E2F2-promoted DNA damage in NASH worsens the metabolic scenario

16. WED-404 - The E2F2-miR34a-5p axis is involved in the biliary metabolism dysregulation in NASH

17. SAT-215 - Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism

18. FRI-395 - E2F2 deficiency protects from acetaminophen-induced hepatotoxicity while E2F1 is required to prevent the devastating effects

19. PS-008-E2F2 mediated repression of fatty acid B-oxidation is mitigated through CREB1 in progressive non-alcoholic fatty liver disease

Catalog

Books, media, physical & digital resources